Suppr超能文献

[急性心肌梗死的最佳再灌注治疗:再灌注时间与再通率]

[Optimal reperfusion therapy in acute myocardial infarction: time to reperfusion and recanalization rate].

作者信息

Mochida Y, Kimura K, Kosuge M, Yoshida K, Iwasawa Y, Hongo Y, Sugiyama M, Ishikawa T, Kuji N, Tochikubo O, Ishii M

机构信息

Critical Care and Emergency Center, Yokohama City University School of Medicine.

出版信息

J Cardiol. 1998 May;31(5):255-62.

PMID:9617655
Abstract

Rapid and complete reperfusion is important for the reduction of infarct size and mortality in acute myocardial infarction. The optimum reperfusion therapy with regard to the recanalization rate and the time elapsing between onset and complete reperfusion was evaluated. One hundred fifty-four patients with total occlusion of the infarct-related artery within 6 hours of the onset were classified into four therapy groups: PTCA group (n = 58) undergoing primary percutaneous transluminal coronary angioplasty (PTCA), t-PA-IC group (n = 44) receiving tissue plasminogen activator (t-PA) intracoronary infusion, t-PA-IV group (n = 14) receiving intravenous t-PA infusion, and mt-PA-IV group (n = 38) receiving intravenous mutant t-PA infusion. Although the recanalization rate was high in the PTCA group, there were no differences between the four groups as a supplement to immediate or rescue PTCA. The time elapsing between initiation of thrombolysis and complete reperfusion was shorter in the mt-PA-IV group than in the t-PA-IV group. Assuming the time from hospital arrival to initiation of intravenous thrombolysis was 20 min, the recanalization rate at 60 min after arrival in hospital was higher in the mt-PA-IV group than the PTCA and t-PA-IC groups. Although additional coronary angiography and PTCA may be required to improve the low recanalization rate compared with primary PTCA, intravenous infusion of mutant t-PA was the most promising therapy to achieve early reperfusion.

摘要

快速和完全再灌注对于降低急性心肌梗死的梗死面积和死亡率很重要。评估了关于再通率以及发病至完全再灌注之间所经过时间的最佳再灌注治疗方法。154例在发病6小时内梗死相关动脉完全闭塞的患者被分为四个治疗组:接受直接经皮冠状动脉腔内血管成形术(PTCA)的PTCA组(n = 58)、接受冠状动脉内输注组织型纤溶酶原激活剂(t-PA)的t-PA-IC组(n = 44)、接受静脉输注t-PA的t-PA-IV组(n = 14)以及接受静脉输注突变型t-PA的mt-PA-IV组(n = 38)。尽管PTCA组的再通率较高,但作为直接或补救性PTCA的补充,四组之间并无差异。mt-PA-IV组从溶栓开始至完全再灌注所经过的时间比t-PA-IV组短。假设从入院到开始静脉溶栓的时间为20分钟,mt-PA-IV组入院后60分钟时的再通率高于PTCA组和t-PA-IC组。尽管与直接PTCA相比,可能需要额外进行冠状动脉造影和PTCA以提高较低的再通率,但静脉输注突变型t-PA是实现早期再灌注最有前景的治疗方法。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验